ストックスクリーナーアプリを入手
5.48
15.37%
0.73
プレマーケット:
6.98
1.50
+27.37%
前日終値:
$4.75
開ける：
$4.65
24時間の取引高:
7.86M
Relative Volume:
1.12
時価総額：
$66.23M
収益：
$1.38M
当期純損益:
$-179.05M
株価収益率:
-0.8925
EPS:
-6.14
ネットキャッシュフロー:
$-155.03M
1週間 パフォーマンス:
+35.64%
1か月 パフォーマンス:
+188.42%
6か月 パフォーマンス:
+137.23%
1年 パフォーマンス:
+705.88%
1日の値動き範囲:
$4.10
$5.49
1週間の範囲:
$4.10
$8.08
52週間の値動き範囲:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
名前
Bioxcel Therapeutics Inc
セクター
電話
203-643-8060
住所
555 LONG WHARF DRIVE, NEW HAVEN, CT
BTAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
5.48 | 65.12M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-21 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-15 | ダウングレード | Mizuho | Buy → Neutral |
| 2023-07-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-03-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-12-01 | アップグレード | Goldman | Sell → Neutral |
| 2022-07-07 | 開始されました | Mizuho | Buy |
| 2022-04-06 | 繰り返されました | BofA Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-30 | 開始されました | Goldman | Buy |
| 2020-09-02 | 開始されました | Jefferies | Buy |
| 2020-08-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-04 | 開始されました | Guggenheim | Buy |
| 2020-04-01 | 開始されました | BofA/Merrill | Buy |
| 2020-02-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
すべてを表示
Bioxcel Therapeutics Inc (BTAI) 最新ニュース
BioXcel Therapeutics Receives Positive FDA Feedback - TipRanks
BioXcel receives FDA alignment for IGALMI at-home use submission - Investing.com
BioXcel stock surges after positive FDA feedback on BXCL501 expansion - Investing.com
BioXcel Therapeutics Announces Positive FDA Pre-sNDA - GlobeNewswire
First-Ever At-Home Agitation Drug: BioXcel's IGALMI Moves Closer to Outpatient Bipolar/Schizophrenia Use - Stock Titan
Bioxcel Therapeutics Soars 18.8% on Phase III Trial Announcement - AInvest
Will Breakout in BioXcel Therapeutics Inc. Sustain Through Next WeekJuly 2025 Price Swings & Technical Buy Zone Confirmations - beatles.ru
BioXcel Therapeutics Inc. Testing Reversal Zone on Weekly ChartEarnings Trend Report & Comprehensive Market Scan Insights - sundaytimes.kr
BioXcel Therapeutics Receives Positive FDA Feedback Ahead of Pre-sNDA Meeting - AInvest
BioXcel Therapeutics Price Target Raised to $10 by H.C. Wainwright Analyst - AInvest
Healthcare Stocks Move in After-Market Session: DIH Holding, Tonix Pharmaceuticals, BioXcel Therapeutics Lead Gainers, Tivic Health Systems, CASI Pharmaceuticals Decline as Losers - AInvest
BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label - Stocktwits
FDA decision coming for BTAI’s at-home agitation drug—will this be the catalyst for a 100% rally - AInvest
Is BioXcel Therapeutics Inc. part of any major indexTrade Volume Summary & AI Enhanced Market Trend Forecasts - thegnnews.com
Bioxcel Therapeutics (BTAI.O) Sees Sharp Intraday Move: What’s Behind the Surge? - AInvest
Bioxcel Therapeutics shares rise 5.68% intraday after HC Wainwright adjusted price target. - AInvest
HC Wainwright Raises PT to $10 for Bioxcel Therapeutics to Buy - AInvest
HC Wainwright Adjusts Price Target on BioXcel Therapeutics to $10 From $8, Maintains Buy Rating - MarketScreener
BioXcel Therapeutics price target raised to $10 from $8 at H.C. Wainwright - TipRanks
BioXcel Therapeutics receives FDA feedback ahead of planned pre-sNDA meeting - Investing.com
Any news on BTAI - AInvest
BioXcel Therapeutics at HCW@Home: Expanding Agitation Treatments By Investing.com - Investing.com Canada
BioXcel Therapeutics at HCW@Home: Expanding Agitation Treatments - Investing.com
Published on: 2025-08-15 03:08:57 - thegnnews.com
BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
3 Supercharged Stocks Flashing Strong Momentum Signals - Benzinga
Mizuho Cuts Price Target for BioXcel Amid Neutral Stance - StocksToTrade
Mizuho Slashes BioXcel Therapeutics’ Price Target, Citing Neutral Outlook - timothysykes.com
BioXcel Therapeutics CEO to participate in virtual fireside chat on Aug 14, 2025. - AInvest
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series - GlobeNewswire
BioXcel Therapeutics CEO Discusses AI-Driven Neuroscience Pipeline at Virtual Investor Event - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates - MSN
Bioxcel Therapeutics 2025 Q2 Earnings Widened Net Loss Amid Revenue Drop - AInvest
BioXcel Therapeutics Reports Q2 2025 Financial Results - TipRanks
BioXcel Therapeutics to Present at Canaccord Genuity 45th Annual Growth Conference on August 12 - AInvest
Bioxcel Therapeutics Sees Significant Market Potential for BXCL501 in Treating Agitation Episodes - AInvest
BioXcel Therapeutics Surges 6.25% on $230M Volume Ranking 441st as Clinical Pipeline and Patent Expansions Bolster Investor Confidence - AInvest
BIOXCEL THERAPEUTICS Earnings Results: $BTAI Reports Quarterly Earnings - Quiver Quantitative
BioXcel Therapeutics (BTAI): Assessing the Impact of SERENITY Trial Outcomes on At-Home Agitation Market Potential - AInvest
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewswire
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials By Investing.com - Investing.com Canada
BioXcel at Canaccord Genuity: Strategic Insights on Phase 3 Trials - Investing.com
BioXcel Therapeutics (BTAI) Q2 Financial Report: Wider Loss, Revenue Decrease, and Upcoming Business Updates - AInvest
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? - Benzinga
Bioxcel Therapeutics (BTAI) up more than 500% since Jul 31 - AInvest
BioXcel Therapeutics Stock Soars Amid Positive Clinical and Patent Developments - StocksToTrade
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics, Inc. SEC 10-Q Report - TradingView
Bioxcel Therapeutics Plunges 12.03% on Q2 Loss, Revenue Drop - AInvest
BioXcel Therapeutics Q2 Earnings Miss Estimates, Revenue Down 89.1% Y/Y - AInvest
Bioxcel Therapeutics Inc (BTAI) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):